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Accepted 24 November 2014; Published online 29 November 2014AbstractObjectives: To assess whether journals are more likely to reject manuscripts with differences between information in registries and
articles. We compared differences by sponsorship and assessed whether selective reporting favored publication of significant outcomes.
Study Design and Setting: Drug trials submitted to eight journals (January 2010eApril 2012) were included. Publication status, primary
outcomes, enrollment, and sponsorship were extracted. Primary outcomes and enrollment in registries and registration timing were reviewed.
Prospective registration included registration before study start. Consistency between registered and reported information was evaluated.
Results: For 226 submitted manuscripts, primary outcomes were specified in both article and registry. Sixty six of 226 (29.2%) had
primary outcome differences; 14 of 66 manuscripts with differences (21.2%) and 46 of 160 without differences (28.8%) were accepted.
Fifty manuscripts (22.4%) had sample size differences; 10 of 50 with differences (20.0%) and 49 of 173 without differences (28.3%) were
accepted. Industry-sponsored trials had less differences and were more often prospectively registered. After adjustment for sponsorship,
differences and/or retrospective registration were not associated with decreased chance of acceptance (odds ratio 0.56; 95% confidence
interval: 0.27, 1.13). Primary outcome differences favored significant outcomes in 49% of manuscripts.
Conclusion: Differences between registered and reported information are not decisive for rejection. Editors should assess consistency
between registries and articles to address selective reporting.  2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Registration of clinical trials in public trial registries
before patient enrollment has been introduced to increase
transparency and accountability in the trial process and to
address selective publication of study results [1,2]. Through
trial registration, investigators should be able to identify all
existing trials, whether published or not, and perform unbi-
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licenses/by-nc-nd/3.0/).intervention. The International Committee of Medical Jour-
nal Editors (ICMJE) enforced such registration in 2005 as a
condition for publication of trial reports in their journals
[2]. Several other medical journals have since adopted
similar policies [3e6].
Although trial registration is now widely implemented,
selective outcome reporting remains to be prevalent among
adequately registered trials [7]. For a substantial proportion
of randomized controlled trials (RCTs) published in high
impact factor journals, evidence of differences between pri-
mary outcomes in trial registries, and peer-reviewed publi-
cations has been found [8e11]. The differences favored
publication of statistically significant outcomes in several
trials [8,9]. Differences have also been detected between
registered and published secondary outcomes, eligibility
criteria, and sample sizes [11e13].
These findings suggest that registered trial information is
not sufficiently being considered during manuscript review
by journals to identify changes to trial characteristics.ess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 A substantial number of manuscripts had differ-
ences between registered and reported information
and/or were retrospectively registered. These arti-
cles were not more likely to be rejected at initial
screening or after peer review.
 Industry-sponsored trials less often had differences
between registered and reported information than
nonindustry and industry-supported trials.
Industry-sponsored trials were also more often pro-
spectively registered.
 For trials registered before completion, primary
outcome differences favored statistically signifi-
cant outcomes in almost 50% of the manuscripts.
What this adds to what was known?
 Previous studies found that selective reporting re-
mains prevalent among registered trials. However,
the role of registered information in editorial deci-
sion making has hardly been assessed. This study
indicates that editors do not take full advantage
of the possibilities provided by registration, as dif-
ferences between registered and reported informa-
tion were found among articles accepted for
publication.
What is the implication and what should change
now?
 Editors and reviewers have the opportunity to iden-
tify changes to trial characteristics and should
routinely assess the consistency between informa-
tion in registries and submitted articles to address
selective reporting and improve the quality of the
publication process.
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ally reported in articles, during initial editorial screening or
peer review, could improve the quality of the publication
process. A limited number of studies have evaluated the
role of registered information in editorial processes. Wager
and Williams [14] showed that only 55 of a sample of 200
journals publishing clinical trials required trial registration
according to their instructions to authors, which was com-
parable to findings of studies with smaller samples of jour-
nals [3,5,6]. A survey among peer reviewers of clinical
trials indicated that only one-third of the reviewers sur-
veyed examined registered information [15]. However, it
has not been investigated whether journals requiring regis-
tration are less likely to publish trials with unacknowledgeddifferences between information in registries and submitted
manuscripts.
Previously, we reported on publication bias in editorial
decision making by evaluating the publication status of
472 drug trials submitted to eight medical journals in rela-
tion to the direction of results and sponsorship [16]. The
aim of this study was to assess whether editors are more
likely to reject submitted manuscripts at initial editorial
screening or after peer review if there are differences be-
tween registered and reported information on the primary
outcome or sample size, using the same set of manuscripts.
In addition, the extent of differences between registries and
manuscripts was compared by sponsor type, and we as-
sessed whether selective outcome reporting favored publi-
cation of statistically significant outcomes.2. Methods
2.1. Selection of journals and submitted manuscripts
Six major general medical journals were asked to pro-
vide access to submitted manuscripts and decisions on pub-
lication. BMJ agreed to participate, and the BMJ Group
also provided access to data of BMJ specialty journals. In
addition, other European specialty journals were asked to
participate. All journals were selected based on (1) impact
factor (journals indexed with the highest impact factors
within subject categories, according to the Institute for Sci-
entific Information Journal Citation Report 2011) and (2)
the number of drug RCTs published in 2010e2011. As a
result, manuscripts submitted to one general medical jour-
nal (BMJ, impact factor 2011 14.093) and seven specialty
journals (Annals of the Rheumatic Diseases, 8.727; British
Journal of Ophthalmology, 2.902; Gut, 10.111; Heart,
4.223; Thorax, 6.840 (all from the BMJ Group); Diabetolo-
gia, 6.814; and Journal of Hepatology, 9.264) were
included. We selected manuscripts on RCTs submitted
from January 2010eApril 2012, if at least one study arm
assessed the efficacy or safety of a drug intervention and
a statistical test was used to evaluate treatment effects. This
cohort of manuscripts has been described in detail previ-
ously [16]. In this study, post hoc and subgroup analyses
of RCTs, follow-up studies of RCTs, and articles reporting
results of O1 trial were excluded because these are not
routinely and/or separately registered.
2.2. Data extraction manuscripts
The primary outcome was acceptance for publication.
Full texts of submitted manuscripts and publication status
were retrieved from manuscript submission systems or pro-
vided by journals. Manuscripts were outright rejected, re-
jected after peer review, or accepted for publication. For
each manuscript, we reviewed the number of participants
and the number and nature of reported primary outcomes.
Primary outcomes were those explicitly reported as such
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stated in the sample size calculation. If none was identified
in the text or sample size calculation, the article was
considered to have no primary outcome reported. Informa-
tion on sponsorship was previously extracted from manu-
scripts and classified according to predefined criteria [17].
In short, trials were classified as nonindustry, industry-
supported, or industry-sponsored. For nonindustry trials,
no associations with pharmaceutical companies were re-
ported. Studies reporting donation of study medication by
a manufacturer, studies stating receipt of financial support
from a pharmaceutical company, and studies with
industry-affiliated authors were classified as industry-
supported trials. For industry-sponsored trials, a pharma-
ceutical company was explicitly described as study sponsor
or the company funding the trial participated in the design,
data collection, analysis, and/or preparation of the manu-
script [17].2.3. Assessment of trial registration
For each manuscript, we assessed trial registration ac-
cording to ICMJE requirements [18]. We checked whether
authors reported registering their trial and whether a regis-
tration number was included in the article or submission
system. When no registration number could be identified,
the trial was considered not registered. All journals
included in this study required trial registration in their in-
structions to authors. Journals published by the BMJ Group
explicitly required that trials were prospectively registered,
whereas Diabetologia and Journal of Hepatology both
referred to ICMJE policy on registration [18], in which trial
registration at or before the time of first patient enrollment
is required.2.4. Data extraction trial registers
For each registered trial, we reviewed the anticipated
sample size and the number and nature of primary out-
comes in the registry. Primary outcomes were outcomes
explicitly reported as such in the registry. If none was iden-
tified, the primary outcome was considered not registered.
To take into account any amendments after initial trial
registration [19], when feasible, we checked changes to
the protocol that were available using the history function
(eg, ‘‘History of Changes’’ on ClinicalTrials.gov archive
site). For each trial, the registration date, start date, and
completion date reported in the registry were extracted. Tri-
als were considered to be prospectively registered when
they were registered before or at the reported start date of
the study. As ClinicalTrials.gov only displays a month
and year for start and completion dates, trials that were
registered in the same month and year as the study start
date were classified as prospectively registered. Trials
registered after the start date (either before or after study
completion) were classified as retrospectively registered.When it was unclear whether a trial was registered before
the start of the study (ie, start and/or end date missing in
registry), trials were considered to be retrospectively regis-
tered. If trials were registered in multiple registries, we ex-
tracted data from the registry in which trial information was
most completely reported.2.5. Definition of differences between registered and
reported information
For manuscripts with primary outcomes specified in
both the registry and the article (sample 1), we assessed
the consistency between registered and reported primary
outcomes and sample sizes. As in previous studies, we
defined differences in primary outcomes according to a
modified classification of Chan et al. [8,9,20]:
1. The registered primary outcome was defined as a non-
primary outcome in the submitted article.
2. The registered primary outcome was omitted in the
submitted article.
3. A new primary outcome was introduced in the sub-
mitted article (ie, an outcome that does not appear
in the registry is introduced as primary in the article).
4. The primary outcome in the submitted article was
described as a secondary outcome in the registry.
5. The timing of assessment of the registered primary
outcome and that reported in the submitted article
was different.
If the registry contained multiple primary outcomes, this
definition was applied for each primary outcome. If the
sample size reported in the manuscript was smaller than
75% of the anticipated sample size specified in the registry,
we scored it as a difference.2.6. Definition of selective outcome reporting
To determine whether selective outcome reporting
favored publication of significant outcomes, trials regis-
tered before completion were selected (sample 2). For tri-
als registered after completion, it was not possible to
evaluate the risk of outcome reporting bias. P-values were
extracted from manuscripts for all registered primary out-
comes and for all outcomes reported in the article.
P! 0.05 was considered statistically significant. A differ-
ence was considered to favor statistically significant out-
comes if [20]:
1. A new significant primary outcome supporting the ef-
ficacy of the test drug was introduced.
2. A nonsignificant primary outcome was omitted or
defined as nonprimary in the article.
3. A new efficacy primary outcome was introduced for a
noninferiority trial, and treatments were equivalent.
If a nonsignificant safety primary outcome (ie, the
experimental drug had no more adverse effects than the
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was not considered as a difference favoring significant out-
comes. If the article contained no data for registered pri-
mary outcomes, the influence of differences could not be
assessed.2.7. Statistical analysis
Descriptive statistics were used to describe included
manuscripts (data presented as frequencies and percent-
ages). We used correlation and regression analyses (univar-
iate and multivariate) to test the relation between
manuscript rejection and differences between registered
and reported trial information. First, the association be-
tween publication status and differences between registered
and reported data and timing of registration was analyzed
using Pearson chi-square tests, adjusted for sponsorship.
Subsequently, the probability of publication was evaluated472 Submitted manuscripts on drug RCTs
369 Manuscripts meeting all inclusion criteria
10
77
RC
19
269 Manuscripts registered
10
91
5 
3 
1 
SAMPLE 1:
226 Manuscripts with primary outcomes 
included in analysis of registered vs reported 
data and editorial decision making
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outcome reporting
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Fig. 1. Flowchart of trial registration and sample swith logistic regression. As the sample of manuscripts with
primary outcomes in both the registry and the article was
relatively small (n 5 226), of which 60 were published,
the number of parameters that could be included in the lo-
gistic model was limited. The effects of the three parame-
ters on acceptance status were similar; therefore, they
were combined in the composite variable ‘‘difference be-
tween registered and reported information (primary
outcome or sample size) and/or retrospective registration’’
in the regression model. We estimated associations between
acceptance (vs. rejection) and trial characteristics with odds
ratios (ORs) and 95% confidence intervals (CIs). To control
for sponsor type, multivariate logistic regression was used
and ORs were calculated. Interaction of the composite var-
iable and sponsorship was evaluated. P! 0.05 was consid-
ered statistically significant. Statistical analyses were
performed using SPSS software (version 20; Chicago,
Illinois).3 Manuscripts excluded
 Post-hoc or subgroup analyses of 
Ts
 Follow-up studies of RCTs
0 Manuscripts excluded
 No registration number in article 
Registration number in article, not traceable in registry
Registration number in article, registry describing    
other trial
Registry in article, number not mentioned
Manuscripts excluded
 No primary outcome specified in registry and/or article
Manuscripts excluded
 Registered after completion
 Time of registration unknown
Reporting results of >1 study
election. RCT, randomized controlled trials.
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Of the 472 manuscripts on drug RCTs submitted from
January 2010 through April 2012, 369 met all inclusion
criteria (Fig. 1). Of these, 73 (19.8%) were submitted to
BMJ, 36 (9.8%) to Annals of the Rheumatic Diseases, 19
(5.1%) to British Journals of Ophthalmology, 93 (25.2%)
to Diabetologia, 59 (16.0%) to Gut, 21 (5.7%) to Heart,
37 (10.0%) to Journal of Hepatology, and 31 (8.4%) to Tho-
rax. Of the 369 manuscripts, 269 (72.9%) were registered,
and for 226 (61.2%), a primary outcome was reported in
both the article and the registry (sample 1). Of these 226 tri-
als, 186 (82.3%) were registered before trial completion
(sample 2).
Of the 269 registered trials, most were registered at
ClinicalTrials.gov (n 5 178, 66.2%), followed by Interna-
tional Standard Randomized Controlled Trial Number Reg-
ister (n 5 27, 10.0%), Australian New Zealand Clinical
Trials Registry (n5 16, 5.9%), and EU Clinical Trials Reg-
ister (n 5 16, 5.9%; Table 1). Most trials were registered
before trial start (n 5 107, 39.8%) or after the start date
but before trial completion (n 5 110, 40.9%). However,
40 (14.9%) were registered after completion, and timing
of registration was unknown for 12 (4.5%) trials. One pri-
mary outcome was reported in the registry for 181 trials
(67.3%), whereas 8 (3.0%) reported no primary outcome,Table 1. Registration characteristics of manuscripts submitted to eight
medical journals (n 5 269)
Characteristic
Registered
manuscripts, n (%)
Total manuscripts 269 (100)
Sponsor type
Nonindustry 114 (42.4)
Industry-supported 85 (31.6)
Industry-sponsored 70 (26.0)
Trial registry
ClinicalTrials.gov 178 (66.2)
ISRCTN 27 (10.0)
ANZCTR 16 (5.9)
EU-CTR 16 (5.9)
Other 32 (11.9)
Timing of registration
Before start of trial 107 (39.8)
Before end of trial, after start date 110 (40.9)
After end of trial 40 (14.9)
Unknown (no dates in registry) 12 (4.5)
Number of primary outcomes registered
0 8 (3.0)
1 181 (67.3)
2 51 (19.0)
3 to 9 29 (10.8)
Number of primary outcomes in article
0 36 (13.4)
1 188 (69.9)
2 34 (12.6)
3 to 7 11 (4.1)
Abbreviations: ISRCTN, International Standard Randomized
Controlled Trial Number Register; ANZCTR, Australian New Zealand
Clinical Trials Registry; EU-CTR, EU Clinical Trials Register.51 (19.0%) had two primary outcomes, and 29 (10.8%)
had three to nine primary outcomes. The number of pri-
mary outcomes reported in articles varied from 0 to 7, with
most trials (n 5 188, 69.9%) reporting one primary
outcome.
Of the 226 manuscripts with primary outcomes in both
the registry and the article (sample 1), 66 (29.2%) had dif-
ferences between registered and reported primary out-
comes, whereas 160 (70.8%) did not (Table 2). Of these,
30 (45.5%) and 60 (37.5%) were outright rejected.
Twenty-two manuscripts (33.3%) with primary outcome
differences were rejected after peer review, compared with
54 (33.8%) without differences. Eventually, 14 manu-
scripts (21.2%) with primary outcome differences and
46 (28.8%) without differences were accepted. Overall,
the pattern of editorial decisions was not significantly
different for manuscripts with or without changed primary
outcomes (P 5 0.418). Differences between registered
and reported sample sizes (ie, sample size in the manu-
script smaller than 75% of the anticipated enrollment
specified in the registry) were found for 50 manuscripts
(22.4%), whereas 173 (77.6%) had no differences
(Table 2). Of these, 19 (38.0%) and 71 (41.0%) were
outright rejected. Twenty-one manuscripts (42.0%) with
sample size differences were rejected after review,
compared with 53 (30.6%) without differences. Ten
(20.0%) manuscripts with sample size differences and
49 (28.3%) without differences were published. Overall
publication status was not significantly different based
on sample sizes differences (P 5 0.271).
For 132 (58.4%) of 226 manuscripts, timing of registra-
tion was retrospective (ie, after trial start date) or unknown,
whereas 94 (41.6%) were prospectively registered
(Table 2). Of these, 59 (44.7%) and 31 (33.0%) were
outright rejected. Forty-three retrospectively registered tri-
als (32.6%) were rejected after review, compared with 33
prospectively registered trials (35.1%). Eventually, 30
(22.7%) retrospectively and 30 (31.9%) prospectively regis-
tered manuscripts were accepted. Overall publication status
did not significantly differ by timing of registration
(P 5 0.154). With regard to the composite variable (‘‘dif-
ference between registered and reported information and/
or retrospective registration’’), 175 trials (77.4%) had a
discrepancy and/or were retrospectively registered, whereas
51 (22.6%) did not (Table 2). Of these, 75 (42.9%) and 15
(29.4%) were outright rejected. Sixty-one manuscripts
(34.9%) with differences and/or retrospective registration
were rejected after review, compared with 15 (29.4%) pro-
spectively registered without differences; 39 (22.3%) and
21 (41.2%) manuscripts were eventually accepted, respec-
tively. The overall publication status was significantly asso-
ciated with the composite variable (P 5 0.024).
Of the nonindustry trials (n 5 89), 31 (34.8%) had pri-
mary outcome differences, compared with 23 (31.5%) of
the trials that were supported by industry (n 5 73) and
12 (18.8%) of the industry-sponsored trials (n 5 64;
Table 2. Publication status of registered manuscripts in relation to differences between registered and reported trial information and timing of
registration (n 5 226)
No differences prospective registration, n (%) Differences retrospective registration, n (%)
P-value
c2-testN
Outright
rejected
Rejected after
peer review Published N
Outright
rejected
Rejected after
peer review Published
Total manuscripts
(n 5 226)
Primary outcome 160 60 (37.5) 54 (33.8) 46 (28.8) 66 30 (45.5) 22 (33.3) 14 (21.2) 0.418
Sample sizea 173 71 (41.0) 53 (30.6) 49 (28.3) 50 19 (38.0) 21 (42.0) 10 (20.0) 0.271
Timing of registration 94 31 (33.0) 33 (35.1) 30 (31.9) 132 59 (44.7) 43 (32.6) 30 (22.7) 0.154
Composite variableb 51 15 (29.4) 15 (29.4) 21 (41.2) 175 75 (42.9) 61 (34.9) 39 (22.3) 0.024
Sponsor type
Nonindustry
(n 5 89)
Primary outcome 58 27 (46.6) 20 (34.5) 11 (19.0) 31 17 (54.8) 11 (35.5) 3 (9.7)
Sample sizea 68 35 (51.5) 23 (33.8) 10 (14.7) 19 9 (47.4) 6 (31.6) 4 (21.1)
Timing of registration 30 12 (40.0) 12 (40.0) 6 (20.0) 59 32 (54.2) 19 (32.2) 8 (13.6)
Composite variable 14 5 (35.7) 4 (28.6) 5 (35.7) 75 39 (52.0) 27 (36.0) 9 (12.0)
Industry-supported
(n 5 73)
Primary outcome 50 22 (44.0) 20 (40.0) 8 (16.0) 23 9 (39.1) 8 (34.8) 6 (26.1)
Sample size 51 24 (47.1) 16 (31.4) 11 (21.6) 22 7 (31.8) 12 (54.5) 3 (13.6)
Timing of registration 28 11 (39.3) 13 (46.4) 4 (14.3) 45 20 (44.4) 15 (33.3) 10 (22.2)
Composite variable 13 5 (38.5) 7 (53.8) 1 (7.7) 60 26 (43.3) 21 (35.0) 13 (21.7)
Industry-sponsored
(n 5 64)
Primary outcome 52 11 (21.2) 14 (26.9) 27 (51.9) 12 4 (33.3) 3 (25.0) 5 (41.7)
Sample sizea 54 12 (22.2) 14 (25.9) 28 (51.9) 9 3 (33.3) 3 (33.3) 3 (33.3)
Timing of registration 36 8 (22.2) 8 (22.2) 20 (55.6) 28 7 (25.0) 9 (32.1) 12 (42.9)
Composite variable 24 5 (20.8) 4 (16.7) 15 (62.5) 40 10 (25.0) 13 (32.5) 17 (42.5)
Abbreviation: N, number of submitted manuscripts.
P-values were calculated using Pearson chi-square tests adjusted for sponsor type.
a Three manuscripts (two nonindustry and one industry-sponsored) reported no sample size in the registry.
b The composite variable is defined as ‘‘difference between registered and reported information and/or retrospective registration.’’
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dustry trials (21.8%), 22 industry-supported trials (30.1%),
and 9 industry-sponsored trials (14.3%). Industry-
sponsored trials were less often retrospectively registered
(43.8%) than industry-supported (61.6%) and nonindustry
trials (66.3%).
In the univariate analysis, the effects found for primary
outcome differences, sample size differences, and timing
of registration were similar (Table 3). The composite vari-
able ‘‘difference between registered and reported informa-
tion and/or retrospective registration’’ was significantly
associated with a decreased chance of acceptance (OR
0.41; 95% CI: 0.21, 0.79). After adjustment for sponsor
type in the multivariate analysis, the composite variable
was no longer significantly associated with publication,
although the direction of the effect was equal to the univar-
iate analysis (OR 0.56; 95% CI: 0.27, 1.13). There was no
interaction of the composite variable and sponsor type
(P 5 0.122).
Among 66 of 226 manuscripts (29.2%) for which pri-
mary outcome differences were detected, 21 articles had
two reasons for a difference in primary outcomes
(Table 4). Differences most often consisted of a registered
primary outcome that was reported as a nonprimary
outcome in the article (34 of 226, 15.0%), followed by
introduction of a new primary outcome in the article (22
of 226, 9.7%). Among 186 of 226 trials (82.3%) that were
registered before completion (sample 2), 49 had primary
outcome differences. Twenty-four of 49 manuscripts
(49.0%) had differences that favored statistically significant
outcomes.4. Discussion
In this study, we focused on the role of registered trial
information in editorial decision making and investigated
whether differences between trial characteristics specified
in registries and those reported in submitted manuscripts
were associated with the chance of subsequent publication.
For almost 30% (66 of 226) of submitted manuscripts on
drug RCTs, we found differences between primary out-
comes in registries and articles. The chance of rejection af-
ter initial editorial screening or peer review was not
substantially different between trials with or without pri-
mary outcome differences. Eventually, 21.2% of manu-
scripts with differences vs. 28.8% of those without
differences were accepted. Interestingly, the proportion of
submitted manuscripts with primary outcome differences
was comparable to that found in previous studies, which
included only published articles [8,10,11,13]. More than
20% (50 of 223) of the manuscripts reported sample sizes
smaller than 75% of the enrollment specified in the registry.
The influence of this difference on rejection rates after
initial screening or peer review was modest. Acceptance
rates for trials with and without sample size differences
were 20.0% vs. 28.3%, respectively. For almost 60% (132
of 226) of the trials, timing of registration was retrospective
or unknown. Publication status did not significantly differ
by timing of registration, and 22.7% of the retrospectively
registered trials vs. 31.9% of those registered prospectively
were accepted. The univariate analysis indicated that the
composite variable ‘‘difference between registered and re-
ported information and/or retrospective registration’’ was
Table 3. Characteristics of registered manuscripts and their association with publication (accepted vs. all rejected) (n 5 226)
Characteristic Total n (%) Published n (%a) OR (95% CI) univariate
Total manuscripts 226 (100) 60 (26.5)
Different primary outcome in registry and article
No 160 (70.8) 46 (28.8) 1.00
Yes 66 (29.2) 14 (21.2) 0.67 (0.34, 1.32)
Different sample size in registry and articleb
Sample size article 75% of registered sample size 173 (77.6) 49 (28.3) 1.00
Sample size article !75% of registered sample size 50 (22.4) 10 (20.0) 0.63 (0.29, 1.36)
Timing of registration
Prospective 94 (41.6) 30 (31.9) 1.00
Retrospective or unknown 132 (58.4) 30 (22.7) 0.63 (0.35, 1.14)
Difference between registered and reported information
and/or retrospective registration
No 51 (22.6) 21 (41.2) 1.00
Yes 175 (77.4) 39 (22.3) 0.41 (0.21, 0.79)
Sponsor type
Nonindustry 89 (39.4) 14 (15.7) 1.00
Industry-supported 73 (32.3) 14 (19.2) 1.27 (0.56, 2.87)
Industry-sponsored 64 (28.3) 32 (50.0) 5.36 (2.53, 11.37)
OR (95% CI) Multivariate
Difference between registered and reported information
and/or retrospective registration
No 1.00
Yes 0.56 (0.27, 1.13)
Sponsor type
Nonindustry 1.00
Industry-supported 1.26 (0.55, 2.85)
Industry-sponsored 4.80 (2.23, 10.31)
Abbreviations: OR, odds ratio; CI, confidence interval.
a Percentage of row category that was accepted for publication.
b Three manuscripts reported no sample size in the registry. ‘‘Sponsor type’’ and ‘‘Difference between registered and reported information and/
or retrospective registration’’ were included in the multivariate model.
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this association was not significant after adjusting for
sponsor type.Table 4. Type of differences between registered and reported primary
outcomes (n 5 226) and selective outcome reporting (n 5 186)
Registered
manuscripts,
n (%)
Total manuscripts 226 (100)
Different primary outcome in registry and article 66 (29.2)
Type of differencea
Registered primary outcome defined as nonprimary
outcome in article
34 (15.0)
Registered primary outcome omitted in article 14 (6.2)
New primary outcome introduced in article 22 (9.7)
Primary outcome in article described as secondary
outcome in registry
12 (5.3)
Different timing of assessment of primary outcome 5 (2.2)
Total manuscripts registered before trial completion 186 (82.3)
Difference favoring statistically significant outcomes 49b
Yes 24 (49.0)
No 15 (30.6)
Impossible to conclude 10 (20.4)
a Twenty-one articles had two reasons for difference in primary
outcome. Therefore, the total % of type of differences is O29.2%.
b Of 186 trials registered before completion, 49 had differences
between registered and reported primary outcomes.Industry-sponsored trials less often had primary
outcome and sample size differences than nonindustry or
industry-supported trials. This corresponds to findings of
a recent study that examined trials submitted to a Dutch
research ethics committee indicating that nonindustry trials
had significantly more problems in recruiting the required
number of subjects than studies initiated by pharmaceutical
companies [21]. Trials not including the required number of
subjects may have lower chances of meeting the study ob-
jectives, and subjects may be unnecessarily exposed to risks
and burdens [21,22]. In contrast, we found that only 5.8%
(13 of 223) of the manuscripts reported sample sizes larger
than 125% of the enrollment specified in the registry.
For manuscripts that were registered before trial comple-
tion, we found that primary outcome differences favored
statistically significant results in almost 50% (24 of 49)
of the manuscripts. This number lies between the propor-
tions reported in previous studies [8,9]. Our study sample
was too small to determine whether selective outcome re-
porting in favor of significant outcomes was associated with
sponsor type.
In agreement with previous studies, approximately a
quarter of the trials were not registered [8,9,13,23].
Industry-sponsored and industry-supported trials were more
often registered than nonindustry trials. Both the timing and
quality of registration should be improved, as only 40% of
1066 M. van Lent et al. / Journal of Clinical Epidemiology 68 (2015) 1059e1067the trials were prospectively registered and primary out-
comes or sample sizes were missing for several trials.
Similar findings regarding the timing and accuracy of regis-
tration have previously been shown, and investigators have
emphasized that without adequate registration, the potential
to address selective publication is limited [24e26].
This study is strengthened by the inclusion of submitted
manuscripts, instead of only published articles [8e13]. By
including both rejected and accepted articles, we were able
to evaluate the role of registered information in editorial de-
cision making. Furthermore, as we selected manuscripts
submitted from 2010 to 2012, the number of trials that
started enrollment before the implementation date of the
ICMJE policy on prospective registration (ie, July 1,
2005) was most likely lower than in previous studies
including trials published in earlier years [8e11].
This study has some limitations. We determined trial
registration by checking whether authors reported regis-
tering their trial and included a registration number. We
have not contacted authors or searched registries to iden-
tify trial records if no registration number was reported.
We compared registered and reported primary outcomes
and sample sizes, although differences may also be com-
mon for other trial characteristics including secondary out-
comes, eligibility criteria, and trial interventions [10,11]
and for results and adverse events reported in the
ClinicalTrials.gov results database [27,28]. In addition, it
could be argued that sample size and primary outcome dif-
ferences are not completely comparable. Differences be-
tween registered and reported sample sizes may reflect
problematic recruitment and may not necessarily constitute
a reporting quality issue as with changed primary
outcomes.
Furthermore, trial protocol amendments that occur dur-
ing the course of a trial, after initial registration, may not
always be accurately reported in the registry. This may in
part explain the observed difference among industry-
sponsored trials and those with other funding sources
regarding the extent of differences between registered and
reported information. Through better administrative sup-
port, registered information may be more adequately up-
dated for industry-sponsored trials in case of protocol
amendments [19].
Finally, although all journals required trial registration,
there may be variation among journals in how strictly this
policy is being enforced. Some journals may insist that
registered information and the timing of registration are
verified as part of an initial check of submitted articles,
whereas others may do little to assess whether authors
comply with requirements [14]. Overall, we found that
rejection rates for manuscripts that were retrospectively
registered or had primary outcome or sample size differ-
ences were not substantially increased, but it was not
possible to assess for individual journals whether they actu-
ally only considered prospectively registered manuscripts
without unacknowledged differences between registeredand reported information. A survey among editors may pro-
vide more insight.
Although introduction of the ICMJE requirement of
prospective trial registration in 2005 led to a large increase
in the number of trial registrations [29], our study and
prior research indicate that editors and reviewers do not
take full advantage of the possibilities provided by regis-
tration [8,9,14,15]. Although editors and reviewers who
evaluated manuscripts included in this study had the op-
portunity to identify changes to trial characteristics and
address selective outcome reporting, we found inconsis-
tencies between registered and reported information
among articles that were accepted for publication. The
consistency between articles and registries should be
routinely and thoroughly checked by journal staff to iden-
tify any changes. If necessary, editors should require ex-
planations from authors which could be explicitly
reported in published articles.
In conclusion, differences between trial information
specified in registries and that reported in submitted manu-
scripts were not a decisive factor for rejection after initial
editorial screening or after peer review. Editors should
assess the consistency between registries and articles to
address selective reporting and improve the quality of the
publication process.Acknowledgments
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